Search PubMed⌕ Search

Biomedical subjects

G N Wogan

Publications and source records attributed to G N Wogan.

At least 73 records · Page 4Linked to original sources

Characterization of c-Ki-ras oncogene alleles by direct sequencing of enzymatically amplified DNA from carcinogen-induced tumors.

Activated c-Ki-ras genes in liver tumors from rats exposed to the potent hepatocarcinogen aflatoxin B1 were analyzed to determine the nature of their activation by characterization of two c-Ki-ras alleles present in tumor-derived NIH 3T3 mouse transformants. Using selective hybridization of synthetic oligonucleotides to transformant DNA, we have determined that a single G X C to A X T base transition in either the first or second position of the 12th codon is associated with activation of the gene. Such mutations would lead to amino acid substitutions of aspartate or serine for glycine in the mutant proteins. To confirm these findings, we applied a technique for direct sequence analysis of a 90-base-pair region of the rat c-Ki-ras gene produced by primer-directed enzymatic amplification. Findings produced by this approach, which provides a convenient method to characterize mutations in multiple alleles without the necessity to clone individual genes, confirmed the presence and identity of the 12th codon mutations in the activated oncogene, as initially determined by the oligonucleotide hybridization technique.

Aflatoxin B1↗

N-methyl-N'-nitro-N-nitrosoguanidine and benzo[a]pyrene-7,8-diol-9,10-epoxide inhibit glucocorticoid-inducible polyoma virus middle-T gene expression in rat mT-1 cells by a post-transcriptional mechanism.

Treatment of rat mT-1 cells with N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) and benzo[a]pyrene-7,8-diol-9,10-epoxide (BPDE) inhibited the steroid-induced expression of the polyoma virus middle-T (mT) gene. Rat mT-1 cells were derived from normal F111 fibroblasts transfected with a plasmid (pSVM-mT) containing a mT cDNA sequence linked to the mouse mammary tumor virus long terminal repeat, thus rendering the mT gene responsive to glucocorticoid hormones. Following a 1-h treatment period with either 100 ng/ml of MNNG or 100 ng/ml of BPDE, administration of 1 microM dexamethasone (DEX) for 24 h resulted in, respectively, 51 and 33% less induction of phosphorylated mT protein in carcinogen-treated than in solvent-treated cells. MNNG appeared to increase the basal level of phosphorylated mT antigen expression by 44%, whereas BPDE had little or no effect on the level of phosphorylated mT protein in uninduced cells. MNNG and BPDE had little or no effect on the level of total steroid-induced mT RNA following addition of DEX for 4 or 20 h. The concentrations of MNNG and BPDE used in these experiments caused, respectively, an 18 and 30% decline in cell number 24 h following carcinogen treatment and had no effect on cell viability as determined by trypan blue exclusion. Previous studies demonstrating the inhibitory effects of chemical carcinogens on the steroid-mediated induction of endogenous genes suggested that carcinogens mediate their effects via a pretranslational mechanism. The present study, using a recombinant DNA construct inserted into the cell genome, provides evidence that carcinogens can inhibit hormone-induced gene expression by a post-transcriptional mechanism as well.

7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide↗

Microsomal activation of fluoranthene to mutagenic metabolites.

The in vitro metabolism of fluoranthene (FA) was assessed by incubating 3-[3H]FA, the synthesis of which is described, with rat hepatic microsomal enzymes. Several metabolites including the FA 2,3-diol, FA 2-3,-quinone, 3-OH-FA, 1-OH-FA, and 8-OH-FA were isolated by high-pressure liquid chromatography and identified by comparison of chromatographic properties and uv-visible spectra with those of synthetic standards. The major metabolite produced over the FA concentration range studied (23-233 microM) was FA 2,3-diol, accounting for 29-43% of the total extractable metabolites. This diol was characterized further by high-resolution mass spectroscopy and H-NMR and determined to be identical in structure to the trans-2,3-dihydroxy-2,3-dihydrofluoranthene. The FA 2,3-diol, syn and anti 2,3-diol-1,10b-epoxides, FA 2,3-quinone, and FA 7,8-diol were all shown to be mutagenic toward Salmonella typhimurium TM677. The FA 1,10b-diol and syn and anti FA 1,10b-diol-2,3-epoxides were not mutagenic. The epoxide hydrolase inhibitor, 3,3,3-trichloropropylene oxide, markedly reduced the mutagenic potency of FA while concurrently inhibiting FA 2,3-diol production but not overall FA metabolism. These results suggests that a major metabolic activation pathway of FA resulting in the production of mutagenic species involves the formation of the FA 2,3-diol and the subsequent oxidation of this diol to a FA 2,3-diol-1,10b-epoxide. Another minor activation pathway with mutagenic endpoints may involve the formation of the 7,8-diol.

Animals↗

Identification of an activated c-Ki-ras oncogene in rat liver tumors induced by aflatoxin B1.

Weanling male Fischer rats were administered 40 intraperitoneal injections of aflatoxin B1 (25 micrograms per animal per day) over a 2-month period. This chronic dosing regimen resulted in the sequential formation of hyperplastic foci, preneoplastic nodules, and hepatocellular carcinomas in all of the animals treated. The presence of transforming DNA sequences was detected by formation of anchorage-independent foci after transfection of tumor-derived DNA in NIH 3T3 mouse fibroblasts. Transfection of genomic DNA isolated from individual tumors from eight animals resulted in specific transforming activities ranging from 0.05 to 0.2 foci per micrograms of DNA. Primary transfectant DNAs were analyzed by Southern blot hybridization with DNA probes homologous to c-Ha-ras, c-Ki-ras, and N-ras oncogenes. A highly amplified c-Ki-ras oncogene of rat origin was detected in transformants derived from tumors in two of the eight animals tested. There was no evidence to suggest the presence of c-Ha-ras or N-ras sequences in any of the transformants. Analysis of primary liver tumor DNA showed no Ki-ras DNA amplification when compared to control liver DNA samples. Increased levels of c-Ki-ras p21 proteins were detected in 3T3 transformants containing activated rat c-Ki-ras genes. The presence of c-Ki-ras sequences of rat origin capable of inducing transformed foci can be taken as evidence that the c-Ki-ras gene has been activated in the primary liver tumors.

Aflatoxin B1↗

In vitro DNA-binding of microsomally-activated fluoranthene: evidence that the major product is a fluoranthene N2-deoxyguanosine adduct.

Incubation of 3-[3H]fluoranthene with a rat liver microsomal activation system in the presence of calf thymus DNA resulted in radioactivity bound to the DNA. The fluoranthene-modified DNA was enzymatically digested and a DNA adduct elution profile developed using h.p.l.c. The fraction containing the major fluoranthene--DNA adduct was further purified by h.p.l.c. and separated into two subfractions. Treatment of these with perchloric acid liberated guanine in both cases. Evidence that both were N-2 guanine derivatives was based on the pK values of these adducts determined before and after treatment with nitrous acid. The major adduct (70% of total modified deoxyribonucleosides) was further characterized by high resolution, fast atom bombardment mass spectroscopy which yielded a molecular ion consistent with a fluoranthene triol bound to the N-2 position of deoxyguanosine. Synthetic syn and anti 3-[3H]2,3-dihydroxy-1,10b-epoxy-1,2,3-trihydrofluoranthene were reacted directly with DNA and the 8-[3H]-7,8-dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrofluoranthene was incubated with DNA and microsomes. The DNA from each of these reactions was enzymatically hydrolyzed and h.p.l.c. adduct profiles were developed. The major adduct formed from reaction of the anti 2,3-dihydroxy-1,10b-epoxy-1,2,3-trihydrofluoranthene with DNA and the major N-2 fluoranthene derived adduct had identical elution times on two different h.p.l.c. systems, similar pK values (before and after nitrous acid treatment) and the same u.v. spectra. In addition, derivatization of both adducts with ethyl methanesulfonate yielded identical products, as determined by h.p.l.c. analysis.

Animals↗

Inhibition of steroid-inducible tyrosine aminotransferase gene expression by N-methyl-N'-nitro-N-nitrosoguanidine in a rat hepatoma cell line.

Treatment of rat hepatoma cells (the Fao clone of Reuber H35 cells) with a 500 ng/ml concentration of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) caused a marked inhibition of steroid-inducible tyrosine aminotransferase (TAT) gene expression. Following a 1-h treatment period with MNNG, addition of 1 microM dexamethasone (DEX) for 6 and 24 h resulted in, respectively, 78 and 51% less induction of TAT enzyme activity in MNNG-treated than in solvent-treated cells. MNNG had little effect on the basal level of TAT activity 6 h after treatment with the carcinogen, but the uninduced level of TAT activity declined to 36% of the control value 24 h following MNNG treatment. MNNG-treated cells concurrently exhibited 75% less total steroid-induced TAT RNA following addition of 1 microM of DEX for 4 h, but showed little or no change in the basal level of total TAT RNA or in the level of total alpha-tubulin RNA. In addition, MNNG treatment resulted in 45% less induction of TAT enzyme activity following a 4-h treatment period with 0.5 mM N6,O2'-dibutyryl-adenosine 3',5'-cyclic monophosphate. The concentration of MNNG used in these experiments caused only a 14% decline in cell number 24 h following carcinogen treatment and had no effect on cell viability as determined by trypan blue exclusion. The data indicate that the inhibitory effects of MNNG appear to be mediated at a pre-translational step. MNNG inhibits the accumulation of total DEX-inducible TAT RNA either by preventing the steroid-mediated increase of the rate of TAT RNA transcription or decreasing total TAT RNA stability, or both.

Animals↗

Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography.

A high-affinity IgM monoclonal antibody specific for aflatoxins was covalently bound to Sepharose 4B and used as a preparative column to isolate aflatoxin derivatives from the urine of people and experimental animals who had been exposed to the carcinogen environmentally or under laboratory conditions. Aflatoxin levels were quantified by radioimmunoassay and high-performance liquid chromatography after elution from the affinity column. In studies on rats injected with [14C]aflatoxin B1, we identified the major aflatoxin-DNA adduct, 2,3-dihydro-2-(N7-guanyl)-3-hydroxy-aflatoxin B1 (AFB1-N7-Gua), and the oxidative metabolites M1 and P1 as the major aflatoxin species present in the urine. When this methodology was applied to human urine samples obtained from people from the Guangxi Province of China exposed to aflatoxin B1 through dietary contamination, the aflatoxin metabolites detected were also AFB1-N7-Gua and aflatoxins M1 and P1. Therefore, affinity chromatography using a monoclonal antibody represents a useful and rapid technique with which to isolate this carcinogen and its metabolites in biochemical epidemiology and for subsequent quantitative measurements, providing exposure information that can be used for risk assessment.

Aflatoxin B1↗

6-Nitrochrysene is a potent tumorigen in newborn mice.

A newborn mouse (BLU:Ha) lung adenoma bioassay demonstrated that 6-nitrochrysene was a highly potent tumorigen. It induced 100% incidence of lung tumors and a 150-fold increase in their number (20.84 tumors/mouse) at the lowest dose level tested (total dose: 38.5 micrograms/mouse). 70% of the 6-nitrochrysene treated mice had malignant lung tumors (adenocarcinomas). Lymphomas and nodular hyperplasia of the liver were also observed in treated, but not control, animals. The tumorigenicity of 6-nitrochrysene relative to other polynuclear aromatic hydrocarbons and their mononitro-derivatives has been discussed.

Adenoma↗

Chemical and biochemical dosimetry of exposure to genotoxic chemicals.

Epidemiologic studies designed to evaluate the health significance of environmental chemicals are compromised by the lack of quantitative exposure data for individuals in exposed populations. Monitoring data on levels of compounds in environmental media often represent the only information available, and average population exposure is therefore the only quantitative parameter that can be calculated. Biological monitoring, i.e., measurements on cells, tissues or body fluids of exposed persons, has the objective of defining the so-called "internal dose" or "effective dose" on an individual basis. Such measurements can be used to ensure that current or past exposure does not entail unacceptable health risks, or can detect potentially excessive exposure before the appearance of adverse health effects. Results obtained through this approach can be interpreted on an individual basis and also used to estimate for that individual the amount of chemical absorbed during a specific time interval or the amount bound to critical sites. They may also be useful for characterization of community exposure by analyzing results obtained in groups of individuals within the general population. In this respect, biological monitoring data complement environmental measurements but have certain advantages in estimating health risks. Most importantly, the data obtained are more directly related to adverse effects and thus provide a better estimate of risk than ambient monitoring. Biological monitoring also takes into account absorption by all routes, integrates exposure from all sources, and therefore can be used as a basis for estimate of total risk from multiple chemicals.

Animals↗

Diet and nutrition as risk factors for cancer.

Involvement of diet and nutrition as risk factors for human cancers has been established by two general types of evidence. Epidemiological studies in human populations have identified associations between patterns of incidence for various forms of cancer and diet composition or food consumption patterns. Such associations are particularly evident in studies on migrant populations and in patterns of geographic localization of specific forms of cancer. Reduction in gastric cancer (and increase in colon cancer) incidence has been observed in immigrants from Japan to the U.S. via Hawaii with concurrent change in dietary habits. High fat consumption has been linked to increased incidence of breast and colon cancer, and evidence is accumulating that suggests increased intake of dietary fiber (or some specific component of it) may be associated with diminished risk of colorectal cancer. Laboratory studies have demonstrated the existence of dietary constituents that might impact cancer risk in people consuming them. Substances in this class fall into two general categories: genotoxic carcinogens/mutagens; and protective factors which inhibit experimentally-induced chemical carcinogenesis in animals. Numerous naturally-occurring carcinogens/mutagens have been identified. Examples include aflatoxins, cycasin, and bracken fern carcinogen(s), among others. Genotoxic substances associated with the use of intentional food additives are the N-nitroso compounds formed as nitrosation products from nitrite. Potential carcinogenic risk from food constituents also comes from mutagens found in foods as natural components, or formed in the course of cooking.(ABSTRACT TRUNCATED AT 250 WORDS)

Carcinogens↗

Quantitative and qualitative characterization of aflatoxin B1 adducts formed in vivo within the ribosomal RNA genes of rat liver DNA.

We have examined the time course and patterns of covalent aflatoxin B1:DNA adducts produced within the ribosomal RNA gene sequences isolated from the liver nuclear DNA of aflatoxin B1-treated animals. Liver nuclear DNA was initially enriched in ribosomal DNA by cesium salt density centrifugation, and incubated under alkaline conditions to stabilize bound aflatoxin B1-DNA moieties. Alkali-treated DNA was hybridized to 18S and 28S rRNA, and the RNA:DNA hybrids were recovered by cesium chloride centrifugation. Ribosomal DNA sequences within nuclear DNA were found to be preferential targets for aflatoxin B1 modification. Over a 12-h period after administration of 1-mg [3H]aflatoxin B1/kg dose ribosomal DNA contained 4 to 5 times more aflatoxin B1 residues per mg DNA than did total nuclear DNA. Aflatoxin B1 residues bound to ribosomal DNA were also found to be removed more rapidly than from total nuclear DNA by a factor of 5.7 over the 12-h period postdosing. Levels of the principal aflatoxin B1 adduct, 2,3-dihydro-3-hydroxy(N7-guanyl)aflatoxin B1, as well as the stable formamidopyrimidine derivatives of the parent adduct were also determined. Nuclear DNA isolates were heated to induce depurination of the principal N7-guanine adduct, and differences in adduct levels between alkali-treated (stabilized) and depurinated DNA samples were taken as an approximation of initial levels of this aflatoxin B1:DNA moiety in ribosomal isolates. No differences in the proportions of these aflatoxin B1:DNA adduct species were found in ribosomal as compared to total nuclear DNA, and we conclude that the preferential formation and removal of aflatoxin B1:DNA moieties within ribosomal DNA is not associated with a pattern of adducts qualitatively different from that in total nuclear DNA.

Aflatoxin B1↗

Carcinogenicity in rats of the nitrosated bile acid conjugates N-nitrosoglycocholic acid and N-nitrosotaurocholic acid.

Two nitrosated bile acid conjugates, N-nitrosoglycocholic acid and N-nitrosotaurocholic acid, were examined for carcinogenicity in a 2-year study with male Fischer rats using a 6-week p.o. dosing protocol with a total of 300 mg compound/rat. Both compounds were approximately equally carcinogenic and induced significant levels of hepatocellular carcinoma in 54 to 70% of the animals at risk. Gastric tumors of the glandular and aglandular stomach were observed in 12 to 13% of the treated rats. Although the incidence was not significant, these levels were much higher than those in historic controls. Malignant liver and gastric tumors were not detected in vehicle control rats. Alkaline phosphatase-positive foci, putative early mucosal alterations which may precede neoplasia, were found in approximately 35% of the glandular stomachs of compound-treated rats but not in those of control rats.

Alkaline Phosphatase↗

High-affinity monoclonal antibodies for aflatoxins and their application to solid-phase immunoassays.

Monoclonal antibodies specific for aflatoxin B1, aflatoxin B2, aflatoxin M1, and the major aflatoxin-DNA adducts were obtained following fusion of mouse SP-2 myeloma cells with spleen cells of mice immunized with aflatoxin B1 covalently bound to bovine gamma globulin. The aflatoxin-modified protein used to immunize mice was produced chemically by activating aflatoxin B1 to a 2,3-epoxide derivative, which then covalently bound to the protein. One of the monoclonal antibodies isolated (2B11) was found to be a high-affinity IgM antibody with an affinity constant for aflatoxin B1, aflatoxin B2, and aflatoxin M1 of about 1 X 10(9) liters per mol. In a competitive radioimmunoassay using [3H]aflatoxin B1, 3 pmol (1 ng) of aflatoxin B1, aflatoxin B2, or aflatoxin M1 caused 50% inhibition with this antibody. The antibody also had significant cross-reactivity for the major aflatoxin-DNA adducts: 2,3-dihydro-2-(N7-guanyl)-3-hydroxyaflatoxin B1 and 2,3-dihydro-2-(N5-formyl-2',5', 6'-triamino-4'oxo-N5-pyrimidyl)-3-hydroxyaflatoxin B1. The antibody was also covalently bound to Sepharose-4B and used in a column-based solid-phase immunosorbent assay system. Aflatoxins added in vitro to phosphate buffer, human urine, human serum, or human milk at levels expected to be obtained in human samples acquired from environmentally exposed individuals were quantitatively recovered by applying the mixture to this antibody affinity column purification system. Preliminary studies using urine samples from rats injected with radiolabeled aflatoxin B1 have also indicated that aflatoxin metabolites can be isolated by these methods. Furthermore, we have found that the monoclonal antibody affinity columns can be regenerated for multiple use. Therefore, the monoclonal antibodies and their application to affinity chromatography represents a useful and rapid technique to purify environmentally occurring levels of this carcinogen and some of its metabolites for quantitative measurements.

Aflatoxin B1↗

Quantitation of aflatoxin B1 adduction within the ribosomal RNA gene sequences of rat liver DNA.

The in vivo formation of covalent aflatoxin B1 (AFB1)-DNA adducts within the rRNA gene sequences of nuclear DNA has been studied in AFB1-treated rats. Liver nuclear DNA, enriched in ribosomal DNA (rDNA) by one round of cesium salt density gradient centrifugation, was treated under buffered alkaline conditions to convert unstable AFB1-N7-guanine adducts to stable AFB1-formamidopyrimidine derivatives. The alkali-treated DNA was hybridized to 18S and 28S rRNA in 70% formamide buffer to form rRNA X rDNA hybrids. These hybrids were separated from the bulk of nuclear DNA by two rounds of centrifugation in CsCl, and the level of AFB1 adduction to rDNA versus total nuclear DNA was compared as a function of dose 2 hr after AFB1 administration. Over an 8-fold dose range (0.25-2.0 mg of AFB1 per kg of body weight), rDNA contained 4- to 5-fold more AFB1 residues than nuclear DNA, indicating that rDNA is preferentially accessible to carcinogen modification in vivo. While aflatoxin B1 forms adducts with DNA principally at guanine residues, the guanine enrichment of rDNA was insufficient to explain the magnitude of observed preferential AFB1 modification of rDNA. These results support the hypothesis that rDNA regions are preferentially accessible to carcinogen modification because of the diffuse conformation maintained within transcribed genes. This experimental approach permits the quantitative description of carcinogen modification within a defined gene sequence; further refinement of this approach may be useful in defining the precise relationships between covalent chemical-DNA interactions and the alterations in gene expression that result.

Aflatoxin B1↗

Tumorigenicity of fluoranthene in a newborn mouse lung adenoma bioassay.

A 24 week lung adenoma bioassay using newborn mice was employed to determine the tumorigenicity of fluoranthene, a common environmental polynuclear aromatic hydrocarbon. A 6.5-fold elevation of lung tumor incidence (58%) and a 12-fold increase in numbers (1.08 tumors/mouse) was observed in animals treated with the highest dose (3.5 mg/mouse), but no increase in tumor incidence was induced by 700 micrograms/mouse. Benzo[a]pyrene, used as a positive control at a comparatively low dose (280 micrograms/mouse), was highly potent, inducing lung tumors in 94% of the animals and elevating their number by 44-fold (4.0 tumors/mouse). Most of the mice treated with the highest dose of benzo[a]pyrene (1.4 mg/mouse) died with massive injection site sarcomas. Male mice, surviving for 24 weeks in fluoranthene and benzo[a]pyrene treatment groups that developed lung tumors, had 2- to 3-fold more tumors than comparably treated females. This is the first reported evidence of tumorigenicity of fluoranthene. The significance of these findings in terms of bioassay sensitivity and the implications regarding human health have been discussed.

Adenocarcinoma↗

Tumors of the mouse hematopoietic system: their diagnosis and interpretation in safety evaluation tests. Report of a study group.

A nomenclature for tumors of the mouse hematopoietic system is proposed. This nomenclature, which will be particularly appropriate for use in safety assessment studies, employs basic cytologic terminology, and subclassifications may take into consideration tissue sites and the presence or absence of leukemia. Analysis of tumor incidence in any given study can take into account the consolidation or separation of various tumor types as pathological and biological judgment indicates. The proposed system should be easily understood by pathologists and can be related to other species. Safety assessments of substances that induce tumors of the murine hematopoietic tumors are complicated by difficulty in diagnosis, by the possible involvement of oncogenic viruses, and by other factors such as genetics, immune status, endocrine status, and diet. These various influences are evaluated in respect to interpretation of safety evaluation data.

Animals↗